EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Multicenter Evaluation of Decentralized Homologous Recombination Deficiency Testing for Enhanced Molecular Diagnosis of Ovarian Cancer

Gardenia Vargas-Parra iD, Marta Sesé iD, Eva Hernández-Illán, Laia Serrano, Laura Camacho, Rosa Somoza iD, Vanessa López, Cristina Teixido iD, Pedro Jares, Javier Hernández-Losa iD, Beatriz Bellosillo

International Journal of Molecular Sciences · 09.11.2026 · 27 (21) · 10028

DOI: 10.3390/ijms272110028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.11.2026. Verfasst von Gardenia Vargas-Parra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Hospital del Mar Research Institute, Barcelona 08003, Spain. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Homologous Recombination, Molecular Diagnostic Techniques, Cystadenocarcinoma, Serous. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca (Spain), AstraZeneca Farmacéutica Spain. S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Assessment of homologous recombination deficiency (HRD) and tumor BRCA1/2 mutation status in high-grade serous ovarian carcinoma (HGSOC) is clinically relevant for treatment decisions and for identifying tumors that may benefit from poly(adenosine diphosphate–ribose) polymerase inhibitors. The Myriad MyChoice® CDx HRD (M-HRD) assay is an established clinically validated HRD testing platform that is performed as a send-out test. We conducted a multicenter pilot study to assess the analytical feasibility and interlaboratory agreement of decentralized testing using the SOPHiA DDM™ Dx HRD Solution (SG-HRD). Three hospitals each contributed eight clinical HGSOC samples previously tested with M-HRD or with SG-HRD in a send-out platform. All centers independently prepared SG-HRD libraries and sequenced the complete set of 24 samples. Agreement with M-HRD was evaluated separately from comparisons with previous SG-HRD send-out results. Among specimens with interpretable M-HRD, overall percent agreement with local SG-HRD results was 95.0% (19/20), 90.0% (18/20), and 88.9% (16/18) at the three hospitals. BRCA1/2 variant calls were concordant with previous testing. Overall, the comparison with previous analyses by Myriad genetics or with previous SOPHiA GENETICS send-out results showed a high level of agreement, with discordances mainly observed in samples with values close to the classification threshold. The small, selected cohort, limited clinical replication, and absence of treatment-outcome assessment restrict precision estimates, generalizability, and conclusions regarding clinical validity. These findings support the analytical feasibility of decentralized SG-HRD testing, but larger studies are needed to characterize performance across a broader range of specimens and testing conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHomologous RecombinationMolecular Diagnostic TechniquesCystadenocarcinoma, SerousFemaleHumansBRCA1 ProteinBRCA2 ProteinMutationPilot Projects

Stichwörter der Autor:innen

BRCA1BRCA2PARP inhibitorsgenomic instabilityhigh-grade serous ovarian carcinomahomologous recombination deficiencylow-pass whole-genome sequencingmolecular diagnostics

Substanzen

BRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Pathology Department, Hospital del Mar Research Institute, Barcelona 08003, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid 08028, Spain.
  • Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona 08035, Spain.
  • Translational Molecular Pathology, Vall d'Hebron Institut de Recerca, Barcelona 08035, Spain.
  • Molecular Biology CORE, Hospital Clínic de Barcelona, Barcelona 08036, Spain.
  • Pathology Department, Hospital Clínic de Barcelona, Barcelona 08036, Spain.

ORCID-Profile: Gardenia Vargas-Parra, Marta Sesé, Rosa Somoza, Cristina Teixido, Javier Hernández-Losa

Förderung

  • AstraZeneca (Spain)
  • AstraZeneca Farmacéutica Spain. S.A.

Zitieren

APA

Vargas-Parra, G., Sesé, M., Hernández-Illán, E., Serrano, L., Camacho, L., Somoza, R., López, V., Teixido, C., Jares, P., Hernández-Losa, J., & Bellosillo, B. (2026). Multicenter Evaluation of Decentralized Homologous Recombination Deficiency Testing for Enhanced Molecular Diagnosis of Ovarian Cancer. International Journal of Molecular Sciences, 27(21), 10028. https://doi.org/10.3390/ijms272110028

Vancouver

Vargas-Parra G, Sesé M, Hernández-Illán E, Serrano L, Camacho L, Somoza R, et al. Multicenter Evaluation of Decentralized Homologous Recombination Deficiency Testing for Enhanced Molecular Diagnosis of Ovarian Cancer. International Journal of Molecular Sciences. 2026;27(21):10028. doi:10.3390/ijms272110028

BibTeX
@article{VargasParra2026,
  author = {Vargas-Parra, Gardenia and Sesé, Marta and Hernández-Illán, Eva and Serrano, Laia and Camacho, Laura and Somoza, Rosa and López, Vanessa and Teixido, Cristina and Jares, Pedro and Hernández-Losa, Javier and Bellosillo, Beatriz},
  title = {Multicenter Evaluation of Decentralized Homologous Recombination Deficiency Testing for Enhanced Molecular Diagnosis of Ovarian Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {10028},
  doi = {10.3390/ijms272110028}
}
Kostenlos starten →